Publications
Found 41 results
Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 20(2):184-191.
.
2018. Blood-brain-barrier organoids for investigating the permeability of CNS therapeutics.. Nat Protoc. 13(12):2827-2843.
.
2018. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.. Drug Metab Dispos. 46(5):658-666.
.
2018. Comparative dynamics of microglial and glioma cell motility at the infiltrative margin of brain tumours.. J R Soc Interface. 15(139)
.
2018. Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival.. JCO Clin Cancer Inform. 2:1-14.
.
2018. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.. Mol Cancer Ther. 17(9):1893-1901.
.
2018. .
2018. In Vitro Liquid Extraction Surface Analysis Mass Spectrometry (ivLESA-MS) for Direct Metabolic Analysis of Adherent Cells in Culture.. Anal Chem. 90(8):4987-4991.
.
2018. Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.. Nat Commun. 9(1):4904.
.
2018. Microtubule-Based Control of Motor-Clutch System Mechanics in Glioma Cell Migration.. Cell Rep. 25(9):2591-2604.e8.
.
2018. Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier.. J Pharmacol Exp Ther. 365(2):249-261.
.
2018. .
2018. Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.. Mol Cancer Ther. 16(11):2572-2585.
.
2017. Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? Pharmacol Res. 123:10-25.
.
2017. Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.. J Pharmacol Exp Ther. 363(2):136-147.
.
2017. mTCTScan: a comprehensive platform for annotation and prioritization of mutations affecting drug sensitivity in cancers.. Nucleic Acids Res. 45(W1):W215-W221.
.
2017.